A SAS simulation study describing bleeds in hemophilia type A and B patients. Based on the "proof-of-concept study" Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors by Konkle et. al. published in Journal of Thrombosis and Haemostasis, 5: 1904-1913 in 2007. The epidemiology and design of the study are not in accordance with CONSORT and SPIRIT as of December 2019. We observe 22 included patients (11 in each group) allocated from 20 sites in 11 countries. Neither the randomization nor the analysis is stratified by center, and it is possible to question the logistics of the experiment. People have asked if a condition on the number of bleeds (above 4 for each month in the pre-prophylaxis period) introduces bias: The study is a comparison of the effect of dose-difference not the effect of the drug, although the mean of bleeds in the first period is obviously higher than in the second period. Suspic